These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22016628)

  • 1. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
    Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
    Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
    Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
    de Keyser CE; Peters BJ; Becker ML; Visser LE; Uitterlinden AG; Klungel OH; Verstuyft C; Hofman A; Maitland-van der Zee AH; Stricker BH
    Pharmacogenet Genomics; 2014 Jan; 24(1):43-51. PubMed ID: 24263182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
    Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
    Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
    Couvert P; Giral P; Dejager S; Gu J; Huby T; Chapman MJ; Bruckert E; Carrié A
    Pharmacogenomics; 2008 Sep; 9(9):1217-27. PubMed ID: 18781850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
    Romaine SP; Bailey KM; Hall AS; Balmforth AJ
    Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.
    Wu X; Gong C; Weinstock J; Cheng J; Hu S; Venners SA; Hsu YH; Wu S; Zha X; Jiang S; Li Y; Pan F; Xu X
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):240S-247S. PubMed ID: 30336686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
    Santos PC; Gagliardi AC; Miname MH; Chacra AP; Santos RD; Krieger JE; Pereira AC
    Eur J Clin Pharmacol; 2012 Mar; 68(3):273-9. PubMed ID: 21928084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of
    Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
    Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.
    Nagy A; Sipeky C; Szalai R; Melegh BI; Matyas P; Ganczer A; Toth K; Melegh B
    BMC Genet; 2015 Sep; 16():108. PubMed ID: 26334733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
    Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
    Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
    Kaewboonlert N; Thitisopee W; Sirintronsopon W; Porntadavity S; Jeenduang N
    J Clin Pharm Ther; 2018 Oct; 43(5):647-655. PubMed ID: 29575099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
    Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT
    Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.